News
- Author:
- Bruce Jancin
Publish date: March 22, 2021
Second study validates cumulative microscopic inflammation score as independent predictor of colorectal neoplasia.
News
- Author:
- Bruce Jancin
Publish date: March 16, 2021
Physician-to-physician teleconsults and remote patient monitoring are predicted to be growth areas.
News
- Author:
- Bruce Jancin
Publish date: March 15, 2021
The rheumatology workforce shortage is here and growing.
News
- Author:
- Bruce Jancin
Publish date: March 15, 2021
Rheumatologic adverse events associated with immune checkpoint inhibitors can happen later in the course of treatment but also can continue after i...
News
- Author:
- Bruce Jancin
Publish date: March 15, 2021
An enhanced anti-inflammatory diet shows promise for symptom reduction.
News
- Author:
- Bruce Jancin
Publish date: March 12, 2021
Depression and obesity are associated with poor treatment response in PsA.
News
- Author:
- Bruce Jancin
Publish date: March 9, 2021
Speakers at the 2021 Rheumatology Winter Clinical Symposium spotlighted new drug approvals and new mechanisms of action in SLE, as well as promisin...
News
- Author:
- Bruce Jancin
Publish date: March 4, 2021
“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”
News
- Author:
- Bruce Jancin
Publish date: March 3, 2021
Highlights include lymphoma risk reduction with biologics, low-dose corticosteroid risk, stratifying VTE risk, treat-to-target strategies and morta...
News
- Author:
- Bruce Jancin
Publish date: February 25, 2021
Panelists at the 2021 Rheumatology Winter Clinical Symposium discussed the impact JAK inhibitors will have on the management of patients with axSpA...
News
- Author:
- Bruce Jancin
Publish date: February 17, 2021
Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box warnin...
News
- Author:
- Bruce Jancin
Publish date: February 17, 2021
Patients prefer home subQ over IVIg, citing greater feeling of autonomy.
News
- Author:
- Bruce Jancin
Publish date: February 10, 2021
Many key molecular pathways involved in HS pathogenesis can be targeted by commercially available agents having other indications.
News
- Author:
- Bruce Jancin
Publish date: February 10, 2021
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
News
- Author:
- Bruce Jancin
Publish date: February 10, 2021
There is both preclinical and clinical evidence that neoadjuvant therapy may offer a survival advantage over adjuvant therapy.
